Horae Gene Therapy Center; Department of Microbiology and Physiological Systems; Li Weibo Institute for Rare Diseases Research
Immunology of Infectious Disease | Immunopathology | Immunoprophylaxis and Therapy | Immunotherapy | Infectious Disease | International Public Health | Microbiology | Therapeutics | Virus Diseases
A recent report by Yang et al. published in Nature reported a recombinant vaccine utilizing recombinant receptor-binding domain (RBD) of SARS-CoV-2 Spike Protein.This vaccine candidate successfully induced potent functional antibody responses in the immunized mice, rabbits, and non-human primates. The study highlights the critical role of the immunogenicity of the RBD domain upon SARS-CoV-2 infection and the alternate vaccine designs that could serve as effective prophylactics against the pandemic.
COVID-19, pandemic, vaccine, recombinant receptor-binding domain, RBD, SARS-CoV-2 Spike Protein
Rights and Permissions
Copyright © The Author(s) 2020. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
DOI of Published Version
Muhuri M, Gao G. Is smaller better? Vaccine targeting recombinant receptor-binding domain might hold the key for mass production of effective prophylactics to fight the COVID-19 pandemic. Signal Transduct Target Ther. 2020 Oct 6;5(1):222. doi: 10.1038/s41392-020-00317-1. PMID: 33024086; PMCID: PMC7537771. Link to article on publisher's site
Signal transduction and targeted therapy
Muhuri M, Gao G. (2020). Is smaller better? Vaccine targeting recombinant receptor-binding domain might hold the key for mass production of effective prophylactics to fight the COVID-19 pandemic. COVID-19 Publications by UMMS Authors. https://doi.org/10.1038/s41392-020-00317-1. Retrieved from https://escholarship.umassmed.edu/covid19/141
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Immunology of Infectious Disease Commons, Immunopathology Commons, Immunoprophylaxis and Therapy Commons, Immunotherapy Commons, Infectious Disease Commons, International Public Health Commons, Microbiology Commons, Therapeutics Commons, Virus Diseases Commons